My SNP for $1000, my 2008 resolution:
groups of customers coming together around shared genotypes and SNPs, comparing notes about their conditions or backgrounds and identifying areas for further scientific research on their own.
2008-05-28: fill out surveys to strengthen the links between your genetic makeup and open research questions. Sounds a lot more fun than “walking for the cure”.
2015-03-15: 23andme enters drugs. This should be very interesting. To date, they have SNPs from 800k people, and that could grow rapidly. I’d expect them to release new higher resolution kits and make them available at cost to their customers.
23andMe, the Google -backed personal genetics startup, will no longer just sell tests to consumers, or genetic data to pharmaceutical companies. This morning, it announced that it plans to start inventing medicines itself.
2015-06-18: 23andme has 1M customers now. I’m pleased to be among the first 0.2% 🙂
2019-07-16: 23andMe Chip Updates
100s of 23andMe customers tested on those earlier chips have pleaded with the company for some way to get access to its latest features, like the health reports and improved ancestry estimates. Many worried about whether their old data was accurate.
2023-06-01: Now they’re doing cancer drugs, but it’s not obvious why their SNPs matter all that much? It feels they need to rebase their approach on much more powerful technology like full genome sequencing. That said, I’ve yet to receive a benefit from my Nebula 30x DNA sequencing.
23ME’610 is designed to do something similar, by binding to a receptor called CD200R1, which was identified as a promising anti-cancer target by 23andMe scientists studying the 23andMe database. CD200R1 is a cell surface receptor protein that is mostly expressed on human immune cells, specifically cancer-fighting T cells and myeloid cells. Tumor cells can express CD200, the only known binding partner for CD200R1, and use this regulatory protein to turn off the activity of T cells. A drug that blocks the ability of CD200 to bind to CD200R1 may activate T cells and enhance their ability to kill cancer cells.